{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:49Z","timestamp":1772166589025,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017668","name":"Key Research and Development Program of Anhui Province","doi-asserted-by":"crossref","award":["202004j07020034"],"award-info":[{"award-number":["202004j07020034"]}],"id":[{"id":"10.13039\/501100017668","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Secukinumab has been approved by the U.S. FDA and the European Medicines Agency for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with the documented adverse effects. Here we reported in one case that a new symptom, Prurigo Nodularis (PN), developed during the programmed dosing of secukinumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case introduction<\/jats:title>\n                    <jats:p>A 22-years-old male with a 6-month history of severe plaque psoriasis vulgaris was presented to the dermatology clinic two weeks after the fifth serial weekly doses of secukinumab, for the reason of the outbreaks of multiple erythematous papules and pruritus nodules on the trunk and extremities. Physical examination showed that psoriatic rash were under effective control with the previous targeted therapy of secukinumab for plaque psoriasis vulgaris, but new dermatologic condition was spotted with multiple edematous red firm papules on the trunk and extremities, in the form of soy or hemispherical nodules, red in color, firm to touch, with some ulcerated crusts visible at tops, but negative Auspitz sign. Pathological examination confirmed these papules as PN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case report is shared to inform clinicians about an unannounced adverse effect of the secukinumab in the treatment of psoriasis, and it is recommended that patients be carefully informed of the possible risk of PN before starting treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-023-00811-5","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T12:23:59Z","timestamp":1688559839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Qingqing","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajie","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2583-7910","authenticated-orcid":false,"given":"Shengxiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"811_CR1","doi-asserted-by":"publisher","first-page":"19295","DOI":"10.1038\/srep19295","volume":"6","author":"P Varshney","year":"2016","unstructured":"Varshney P, et al. Transcriptome profiling unveils the role of cholesterol in IL-17A signaling in psoriasis. Sci Rep. 2016;6:19295.","journal-title":"Sci Rep"},{"issue":"2","key":"811_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1586\/17512433.2016.1129894","volume":"9","author":"T Jaleel","year":"2016","unstructured":"Jaleel T, et al. Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Rev Clin Pharmacol. 2016;9(2):187\u2013202.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"811_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","volume":"75","author":"PC van de Kerkhof","year":"2016","unstructured":"van de Kerkhof PC, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83\u201398. e4.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"811_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","volume":"15","author":"A Blauvelt","year":"2016","unstructured":"Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016;15(10):1413\u201320.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"811_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjd.12110","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412\u201321.","journal-title":"Br J Dermatol"},{"issue":"10201","key":"811_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139.","journal-title":"Lancet"},{"issue":"6","key":"811_CR7","first-page":"709","volume":"145","author":"E Cozzani","year":"2010","unstructured":"Cozzani E, et al. The quality of life in italian psoriatic patients treated with biological drugs. G Ital Dermatol Venereol. 2010;145(6):709\u201312.","journal-title":"G Ital Dermatol Venereol"},{"issue":"9","key":"811_CR8","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jid.2021.02.749","volume":"141","author":"M Belzberg","year":"2021","unstructured":"Belzberg M, et al. Prurigo Nodularis is characterized by systemic and cutaneous T helper 22 Immune polarization. J Invest Dermatol. 2021;141(9):2208\u20132218e14.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"811_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ejp.767","volume":"20","author":"C Zeidler","year":"2016","unstructured":"Zeidler C, Stander S. The pathogenesis of Prurigo nodularis\u2013\u2018Super-Itch\u2019 in exploration. Eur J Pain. 2016;20(1):37\u201340.","journal-title":"Eur J Pain"},{"issue":"1","key":"811_CR10","doi-asserted-by":"publisher","first-page":"e12751","DOI":"10.1111\/dth.12751","volume":"32","author":"M Burlando","year":"2019","unstructured":"Burlando M, et al. Atopic-like dermatitis after secukinumab injection: a case report. Dermatol Ther. 2019;32(1):e12751.","journal-title":"Dermatol Ther"},{"key":"811_CR11","doi-asserted-by":"crossref","unstructured":"Megna M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol; 2021.","DOI":"10.1111\/ced.15052"},{"issue":"4","key":"811_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamadermatol.2015.4992","volume":"152","author":"OL Quach","year":"2016","unstructured":"Quach OL, Hsu S. Perianal Dermatophytosis during Secukinumab Therapy for Plaque Psoriasis. JAMA Dermatol. 2016;152(4):486\u20137.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"811_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2133.2011.10498.x","volume":"165","author":"S Fukushi","year":"2011","unstructured":"Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165(5):990\u20136.","journal-title":"Br J Dermatol"},{"issue":"3","key":"811_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJMoa1104200","volume":"365","author":"S Eyerich","year":"2011","unstructured":"Eyerich S, et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med. 2011;365(3):231\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"811_CR15","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1097\/DER.0000000000000740","volume":"32","author":"F Russo","year":"2021","unstructured":"Russo F, et al. Psoriasis-like eruption triggered by Dupilumab Therapy. Dermatitis. 2021;32(6):e147\u20138.","journal-title":"Dermatitis"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-023-00811-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-023-00811-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-023-00811-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T12:30:26Z","timestamp":1688560226000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-023-00811-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1186\/s13223-023-00811-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1933792\/v1","asserted-by":"object"}]},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"5 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qingqing Yang, Jiajie Lyu, Yu Gui, Shuling Yu, Jiajie Chen, Haoxue Zhang and Shengxiu Liu declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"59"}}